quantumbiopharma.com (QNTM): Net earnings per share growth forecast for next year
Quantum BioPharma Ltd (QNTM) creates unique therapeutic platforms for subsequent global scaling with high returns. The history of consensus earnings estimates for the coming year allows for a comparison of the company's results with market expectations, where the 0.00 level indicates the state of the parameter. The business's financial stability depends on capital inflows and liquidity, while its environmental profile is limited to standard laboratory waste control.
Analytical breakdowns and data insights for company quantumbiopharma.com (QNTM)
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- company book value details:
- company total debt and liquidity indicators:
Total Debt to Capital Quantum BioPharma Ltd|QNTM - Long-Term Debt to Capital|Short-Term Debt to Equity Quantum BioPharma|QNTM - Company Aggregate Debt|Debt to Book Value Quantum BioPharma|QNTM - Amount of Long-Term Liabilities|Company Current Liabilities Quantum BioPharma|Quick Liquidity quantumbiopharma.com
- net income and valuation ratios data:
QNTM - Net Income|Future Profit Quantum BioPharma Ltd|QNTM - Company Value to Net Income|Forward P/E Multiple Quantum BioPharma Ltd|QNTM - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Quantum BioPharma|QNTM - Operating income before deduction of amortization|Earnings per share for the last twelve months Quantum BioPharma|QNTM - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months quantumbiopharma.com|QNTM - Earnings per share trend in current year|Earnings growth forecast for next year Quantum BioPharma Ltd
General company analysis:Quantum BioPharma Limited
Quantum BioPharma Ltd (QNTM) is currently transforming its asset structure and optimizing costs to implement a new pharmaceutical strategy. This metric measures analyst consensus expectations for net earnings per share (EPS) dynamics, identifying anomalous valuation revisions by investment houses. Investors determine the issuer's financial stability by tracking the projected change in earnings per share for the coming year to assess the effectiveness of the current management restructuring.
Direct competitors
HLN (Haleon Group) - Earnings growth forecast for next year|Expected net earnings per share growth next year Kenvue Health KVUE|Net earnings per share growth forecast for next year Verona Pharma plc (VRNA)|MENS (jyongbio.com) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year Ligand LGND|Net earnings per one share growth forecast for next year Amneal Pharmaceuticals, Inc.|PRGO: Expected earnings per share growth for next year|ALVO - Earnings growth forecast for next year|LQDA: Earnings growth forecast for next year|glpg.com (GLPG) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year ANI Pharmaceuticals, Inc.|Projected earnings per share growth rate for next year MNKD (MannKind Corp)|Expected earnings per share growth for next year AMPH (Amphastar)|Projected earnings per share increase next year PCRX|ARS Pharmaceuticals - Expected earnings per share growth for next year|Earnings growth forecast for next year theravance.com TBPH|AQST - Net earnings per share growth forecast for next year|scPharmaceuticals Inc. (SCPH) - Expected earnings per share growth for next year|TECX (tectonictx.com) - Expected earnings per share growth for next year|Tonix Pharmaceuticals Holding - Expected earnings per share trend next year|SXTC (SXT Pharmaceuticals) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year EPRX|Earnings growth forecast for next year BHST|Consensus forecast of earnings per share growth for next year Invizyne Technologies|Net earnings per share growth forecast for next year Oramed Pharmaceuticals Inc. ORMP|Entera Bio Ltd (ENTX) - Expected net earnings per share growth next year|HYFT - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year ABVC|CPIX: Earnings growth forecast for next year|FibroGen Inc - Expected earnings per share trend next year|TELO (Telomir Pharma) - Earnings growth forecast for next year|Earnings growth forecast for next year Rani Therapeutics Inc|Net earnings per share growth forecast for next year Synergy CHC Corp (SNYR)|RLYB (rallybio.com) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year Lexaria Bioscience Corp. LEXX|PULM - Expected earnings per share growth for next year|Pheton - Earnings growth forecast for next year|APM - Earnings growth forecast for next year|LYRA (Lyra Therapeutics, Inc.) - Expected earnings per share growth for next year|Impact BioMedical, Inc. - Expected earnings per share trend next year|Net earnings per share growth forecast for next year TNF Pharmaceuticals Inc.|Net earnings per share growth forecast for next year YCBD|Expected earnings per share growth for next year PRFX (PainReform Limited)|Projected earnings per share increase next year CYTO|Earnings growth forecast for next year LIPO (Lipella Pharmaceuticals)|OPTN: Projected earnings per share growth rate for next year|PIRS - Net earnings per share growth forecast for next year|Net earnings per one share growth forecast for next year Procaps Group (PROC)|Petros (PTPI) - Net earnings per share growth forecast for next year|Projected earnings per share growth rate for next year QLI|Expected earnings per share growth for next year SLRN|TFFP (tffpharma.com) - Projected earnings per share increase next year
